Latest news
Should FDA Approval of ORZEYFUL for Narcolepsy Type 1 Prompt Action From Takeda Pharmaceutical (TSE:4502) Investors? - simplywall.stsimplywall.st · Sat, 08 Aug 2026 11:46:03 GMTFierce Pharma Asia—Takeda’s historic narcolepsy nod; Daiichi’s accounting error; Astellas’ revenue beat - Fierce PharmaFierce Pharma · Fri, 07 Aug 2026 12:35:10 GMTJennifer Taubert announces retirement from J&J; Takeda’s global TYK2 leader exits - Endpoints NewsEndpoints News · Fri, 07 Aug 2026 11:00:00 GMTTakeda nets first-in-class advantage on narcolepsy drug’s FDA go-ahead - Pharmaceutical TechnologyPharmaceutical Technology · Fri, 07 Aug 2026 09:53:37 GMTTakeda (TAK) insider Nicola Greenway plans sale of 34,603 ADSs - Stock TitanStock Titan · Thu, 06 Aug 2026 21:17:47 GMTTakeda approval ushers in new wave of sleep drugs - BioPharma DiveBioPharma Dive · Thu, 06 Aug 2026 16:10:45 GMTTakeda wins U.S. FDA approval for narcolepsy drug ORZEYFUL - International Business TimesInternational Business Times · Thu, 06 Aug 2026 15:36:29 GMTTakeda Achieves Major Milestone With Holistic Narcolepsy Drug Approval - BenzingaBenzinga · Thu, 06 Aug 2026 15:16:02 GMT